Conor Set To Enroll Pivotal U.S. Study For CoStar, Talks Up DES Pipeline
This article was originally published in The Gray Sheet
Executive Summary
Conor Medsystems expects to begin enrolling a 1,700-patient, U.S. pivotal trial for itsCoStar paclitaxel-eluting, cobalt-chromium coronary stent in the next few weeks